Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
about
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system.A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811.Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.
P2860
Q33708995-C3DF63FB-7126-4415-B7A1-FB7C19667EA8Q37079141-C6553609-91C3-459D-8C88-FA8EA36747FFQ37618829-FB8687E9-0FDC-4A42-8FA8-401FF7AB867CQ37737798-0CD2EE38-0811-4DB8-B1C3-B23176E8509AQ38685006-C4BD9D13-40BC-4195-831E-BBA3515716A3Q38947056-6431686D-2F53-4F2D-8C53-546570B62A62Q39375290-6956E942-50BB-42D1-BC5F-849DEC548B00Q39433833-D5910457-2FD6-40B2-84C2-01B94CB7AC64Q41210218-E16454B6-F5E9-49FE-8D35-4E6EBA4EC253Q46246670-523BA928-058F-4310-86ED-BE4B6012BB0AQ49539698-46D9E762-F043-413A-B7D9-9A83AA4E99C9Q55354182-351AA6B6-244F-432C-A273-46467A9435B0
P2860
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ulocuplumab (BMS-936564 / MDX1 ...... ygen species-dependent pathway
@ast
Ulocuplumab (BMS-936564 / MDX1 ...... ygen species-dependent pathway
@en
type
label
Ulocuplumab (BMS-936564 / MDX1 ...... ygen species-dependent pathway
@ast
Ulocuplumab (BMS-936564 / MDX1 ...... ygen species-dependent pathway
@en
prefLabel
Ulocuplumab (BMS-936564 / MDX1 ...... ygen species-dependent pathway
@ast
Ulocuplumab (BMS-936564 / MDX1 ...... ygen species-dependent pathway
@en
P2093
P2860
P356
P1433
P1476
Ulocuplumab (BMS-936564 / MDX1 ...... ygen species-dependent pathway
@en
P2093
Amine Ale-Ali
Carlos I Amaya-Chanaga
Deepak Kumar
Harrison Jones
Januario E Castro
Laura Z Rassenti
Lewis J Cohen
Michael Y Choi
Michelle R Kuhne
Peter Sabbatini
P2860
P304
P356
10.18632/ONCOTARGET.6465
P407
P577
2016-01-01T00:00:00Z